What is he best known for?
The fields of study he is best known for:
- Internal medicine
- Disease
- Cholesterol
Michael H. Davidson mainly investigates Internal medicine, Endocrinology, Cholesterol, Placebo and Cardiology.
His work on Internal medicine is being expanded to include thematically relevant topics such as Gastroenterology.
His research investigates the connection with Endocrinology and areas like Tolerability which intersect with concerns in Psychiatry.
His Cholesterol research is multidisciplinary, incorporating perspectives in Statin and Simvastatin, Pharmacology.
His Placebo research incorporates themes from Bile acid sequestrant, Dose, Hydroxymethylglutaryl-CoA reductase, Aspirin and Estrogen.
He has researched Cardiology in several fields, including Cilostazol and Vascular disease.
His most cited work include:
- Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* trial) (1159 citations)
- Weight Control and Risk Factor Reduction in Obese Subjects Treated for 2 Years With Orlistat: A Randomized Controlled Trial (790 citations)
- Lipoprotein management in patients with cardiometabolic risk: consensus statement from the American Diabetes Association and the American College of Cardiology Foundation. (666 citations)
What are the main themes of his work throughout his whole career to date?
Michael H. Davidson mainly focuses on Internal medicine, Endocrinology, Cholesterol, Psychiatry and Pharmacology.
His research integrates issues of Gastroenterology, Placebo and Cardiology in his study of Internal medicine.
His Placebo research is multidisciplinary, incorporating elements of Adverse effect and Randomized controlled trial.
The study of Cholesterol is intertwined with the study of National Cholesterol Education Program in a number of ways.
His Psychiatry research is multidisciplinary, relying on both Cohort and Clinical psychology.
Many of his research projects under Pharmacology are closely connected to In patient with In patient, tying the diverse disciplines of science together.
He most often published in these fields:
- Internal medicine (54.73%)
- Endocrinology (30.77%)
- Cholesterol (20.86%)
What were the highlights of his more recent work (between 2014-2021)?
- Internal medicine (54.73%)
- Endocrinology (30.77%)
- Statin (11.54%)
In recent papers he was focusing on the following fields of study:
Michael H. Davidson focuses on Internal medicine, Endocrinology, Statin, Hypertriglyceridemia and Placebo.
Internal medicine connects with themes related to Cardiology in his study.
His study in the fields of Apolipoprotein B under the domain of Endocrinology overlaps with other disciplines such as In patient.
His Statin research integrates issues from Dyslipidemia, Disease, Adverse effect and Clinical trial.
Michael H. Davidson focuses mostly in the field of Hypertriglyceridemia, narrowing it down to topics relating to Eicosapentaenoic acid and, in certain cases, Docosahexaenoic acid and Very low-density lipoprotein.
His studies deal with areas such as Gastroenterology, Schizophrenia, Positive and Negative Syndrome Scale and Tolerability as well as Placebo.
Between 2014 and 2021, his most popular works were:
- AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY GUIDELINES FOR MANAGEMENT OF DYSLIPIDEMIA AND PREVENTION OF CARDIOVASCULAR DISEASE (506 citations)
- Genomic Dissection of Bipolar Disorder and Schizophrenia, Including 28 Subphenotypes (328 citations)
- Statin intolerance – an attempt at a unified definition. Position paper from an International Lipid Expert Panel (203 citations)
In his most recent research, the most cited papers focused on:
- Internal medicine
- Disease
- Diabetes mellitus
The scientist’s investigation covers issues in Internal medicine, Hypertriglyceridemia, Endocrinology, Statin and Cholesterol.
His work carried out in the field of Internal medicine brings together such families of science as Placebo and Cardiology.
His work deals with themes such as Eicosapentaenoic acid, Clinical endpoint and Lipoprotein, which intersect with Hypertriglyceridemia.
As a part of the same scientific family, Michael H. Davidson mostly works in the field of Endocrinology, focusing on Acute pancreatitis and, on occasion, Cost of illness, Chylomicron, Familial Chylomicronemia, Lipoprotein lipase activity and Genetic disorder.
Michael H. Davidson interconnects Adverse effect, Disease and Rosuvastatin in the investigation of issues within Statin.
His Cholesterol research incorporates elements of Blood pressure and Bioinformatics.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
